Advertising of erectile dysfunction products to consumers violates voluntary US guidelines

BMJ 2013; 346 doi: (Published 22 February 2013) Cite this as: BMJ 2013;346:f1225
  1. Bob Roehr
  1. 1Washington

The pharmaceutical drug industry has consistently failed to adhere to its own self regulation guidelines for direct to consumer advertising of erectile dysfunction (ED) drugs, according to a study1 that looked at four years of such advertising in the United States.

The pharmaceutical industry spent just $985m (£647m; €748m) advertising ED drugs to consumers in 1996. The Food and Drug Administration (FDA) loosened regulations on …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to to receive unlimited access to all content on for 14 days.
Sign up for a free trial